<DOC>
	<DOCNO>NCT00770263</DOCNO>
	<brief_summary>Define maximum tolerate dose dose limit side-effects temsirolimus combination wtih erlotinib patient resistant solid tumor</brief_summary>
	<brief_title>Erlotinib Temsirolimus Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Histologic Diagnosis : Patients must histologically cytologically proven solid malignancy resistant conventional therapy effective therapy know . Dose Expansion Phase ONLY : Patients must archive tumor tissue available ( paraffin block , unstained tissue section , tissue core ) . Tumor Mutational Status ( Dose Expansion Phase ONLY ) : Patients must tumor harbor PTEN loss , PIK3CA mutation , , and/or EGFR mutation . Patients KRAS BRAF mutation . Patients must mutational status determine Genomic Pathology Services Washington University ( GPS @ WU ) CLIAcertified laboratory . Dose Expansion Phase ONLY : Patients squamous carcinoma histology , papillary thyroid carcinoma , adenoid cystic carcinoma eligible expansion cohort regardless genetic alterations.. Measurable NonMeasurable Disease : Patients measurable nonmeasurable disease eligible entry study . In addition , patient without measurable nonmeasurable disease also eligible . Measurable lesion define accurately measure least one dimension ( long diameter record ) ≥20 mm conventional technique ( PET , CT , MRI , xray ) ≥10 mm spiral CT scan . All tumor measurement must record millimeter ( decimal fraction centimeter ) . Tumor marker may consider nonmeasurable disease . A positive bone scan , osteoblastic metastasis , pleural peritoneal effusion consider measurable nonmeasurable . Patients lesion eligible entry study . Dose Expansion Phase ONLY : Patients must tumor easily accessible biopsy determine treat physician study PI . Patients must agree mandatory biopsy end cycle 1 treatment . Recovery Prior Therapy : Patients must recover acute toxic effect prior chemotherapy , immunotherapy , radiotherapy prior enter study . No chemotherapy radiotherapy may give within 3 week prior start protocol treatment . No prior therapy erlotinib temsirolimus allow . Age : Patients must ≥18 year old . Because dose toxicity data currently available use temsirolimus combination erlotinib patient &lt; 18 year age , child exclude study , eligible pediatric phase I singleagent trial , available . Performance Status : ECOG 01 study entry . Life Expectancy : Patients must life expectancy great 12 week . Required Laboratory Values : absolute neutrophil count ≥1,500/mm3 platelets ≥100,000/mm3 hemoglobin ≥9.0 g/dL total bilirubin ≤1.5 x ULN AST/ALT ≤3.0 x ULN alkaline phosphatase ≤2.5 x ULN creatinine ≤2.0 x ULN OR creatinine clearance ≥60 mL/min/1.732 patient creatinine level 2.0 mg/dl serum cholesterol ≤350 mg/dL /9.0 mmol/L ( fast ) triglyceride ≤300 mg/dL ( fast ) * PT/INR ≤1.5 , unless patient full dose warfarin stable dose LMW heparin therapeutic INR &gt; 1.5 ≤3 *Patients triglyceride level &gt; 400 mg/dL start lipid lower agent reevaluate within 1 week . If level go ≤400 mg/dL , consider trial continue lipid lowering agent . Temsirolimus primarily metabolize CYP3A4 . Patients receive enzymeinducing antiepileptic drug ( EIAEDs ; e.g. , phenytoin , carbamazepine , phenobarbital ) CYP3A4 inducer rifampin St. John 's wort , may decrease temsirolimus level . A partial list agent interact cytochrome P450 ( CYP3A ) find Appendix AB . Use agent potently inhibit CYP3A ( hence may raise temsirolimus level ) , ketoconazole , discourage , specifically prohibit . Temsirolimus inhibit CYP2D6 , may decrease metabolism ( increase drug level ) drug substrates CYP2D6 , codeine . The appropriateness use agent leave physician discretion . A list drug may potential interaction CYP2D6 find Appendix A . If doubt eligibility base concomitant medication , Principal Investigator , Dr. Andrea WangGillam , contact . All concomitant medication must record . Known Allergies : Patients know hypersensitivity reaction macrolide antibiotic ( erythromycin , clarithromycin , azithromycin ) eligible trial . Sexually Active Patients : For sexually active patient , use adequate contraception ( hormonal barrier method birth control ) require prior study entry duration study participation . Nonpregnant status determine woman childbearing potential . Pregnant nursing woman eligible . HIVPositive Patients : Patients receive antiretroviral therapy ( HAART ) HIV infection exclude study possible pharmacokinetic interaction . Appropriate study undertake patient receive HAART therapy , indicate . Neurologic Status : Patients must active CNS disease . Recovery Intercurrent Illness : Patients must recover uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris cardiac arrhythmia . Informed Consent : Patients must sign Washington University Human Research Protection Office ( HRPO ) approve informed consent . The patient serious medical psychiatric illness would prevent either give informed consent receipt treatment . Inclusion Women Minorities : Entry study open men woman racial ethnic subgroup .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>solid tumor</keyword>
</DOC>